Inhibition of Orbivirus Replication by Fluvastatin and Identification of the Key Elements of the Mevalonate Pathway Involved
Open Access
Abstract
Statin derivatives can inhibit the replication of a range of viruses, including hepatitis C virus (HCV, Hepacivirus), dengue virus (Flavivirus), African swine fever virus (Asfarviridae) and poliovirus (Picornaviridae). We assess the antiviral effect of fluvastatin in cells infected with orbiviruses (bluetongue virus (BTV) and Great Island virus (GIV)). The synthesis of orbivirus outer-capsid protein VP2 (detected by confocal immunofluorescence imaging) was used to assess levels of virus replication, showing a reduction in fluvastatin-treated cells. A reduction in virus titres of ~1.7 log (98%) in fluvastatin-treated cells was detected by a plaque assay. We have previously identified a fourth non-structural protein (NS4) of BTV and GIV, showing that it interacts with lipid droplets in infected cells. Fluvastatin, which inhibits 3-hydroxy 3-methyl glutaryl CoA reductase in the mevalonic acid pathway, disrupts these NS4 interactions. These findings highlight the role of the lipid pathways in orbivirus replication and suggest a greater role for the membrane-enveloped orbivirus particles than previously recognised. Chemical intermediates of the mevalonic acid pathway were used to assess their potential to rescue orbivirus replication. Pre-treatment of IFNAR(−/−) mice with fluvastatin promoted their survival upon challenge with live BTV, although only limited protection was observed.Keywords
Funding Information
- Horizon 2020 Framework Programme (727393)
This publication has 54 references indexed in Scilit:
- Putative Novel Atypical BTV Serotype ‘36’ Identified in Small Ruminants in SwitzerlandViruses, 2021
- Inhibition of Orbivirus Replication by Aurintricarboxylic AcidInternational Journal of Molecular Sciences, 2020
- Zoonotic and emerging orbivirus infectionsScientific and Technical Review, 2015
- Antiserum from mice vaccinated with modified vaccinia Ankara virus expressing African horse sickness virus (AHSV) VP2 provides protection when it is administered 48h before, or 48h after challengeAntiviral Research, 2015
- Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccinesVaccine, 2015
- Novel Virostatic Agents against Bluetongue VirusPLOS ONE, 2012
- Complete Genome Characterisation of a Novel 26th Bluetongue Virus Serotype from KuwaitPLOS ONE, 2011
- Peruvian horse sickness virus and Yunnan orbivirus, isolated from vertebrates and mosquitoes in Peru and AustraliaVirology, 2009
- Assignment of the genome segments of bluetongue virus type 1 to the proteins which they encodeVirology, 1984
- Inhibition of bluetongue and Colorado tick fever orbiviruses by selected antiviral substancesAntimicrobial Agents and Chemotherapy, 1981